

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISS/ODNER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/813,856	03/30/2004	Douglas A. Lappi	66785-017	5576
Cathryn Campl	7590 07/08/200 oell	EXAMINER		
McDERMOTT, WILL & EMERY Suite 700 4370 La Jolla Village Drive			BORIN, MICHAEL L	
			ART UNIT	PAPER NUMBER
	San Diego, CA 92122			
			MAIL DATE	DELIVERY MODE
			07/08/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
Office Action Summary	10/813,856	LAPPI ET AL.				
,	Examiner Michael Borin	Art Unit				
The MAILING DATE of this communication app	Michael Borin  ears on the cover sheet with the					
Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1) Responsive to communication(s) filed on 27 Ma	1) Responsive to communication(s) filed on 27 March 2009.					
·=	, —					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4)⊠ Claim(s) <u>25-56</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5)∭ Claim(s) <u>25-40</u> is/are allowed. 6)∭ Claim(s) <u>41-56</u> is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or	r election requirement.					
Application Papers						
9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11)☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:						
1.☐ Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)						
1) Notice of References Cited (PTO-892)	4) Interview Summary					
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08)	Paper No(s)/Mail Date  5) Notice of Informal Patent Application					
Paper No(s)/Mail Date <u>03/27/2009</u> .	6) Other:					

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this

application is eligible for continued examination under 37 CFR 1.114, and the fee set

forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action

has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on

03/27/2009 has been entered.

The pending claims were discussed with applicant's representative, Astrid R.

Spain around 06/22/2009. Insofar as applicants thereafter did not contact Examiner to

inform whether the suggestions to amend the claims to allowable form are acceptable,

the following Office action was deemed necessary.

Status of the claims

Claims 26,27 are amended to remove "comprising" language. New claims,

claims 41-56, are added, which are parallel to previously examined claims 25-36 but

are directed to conjugates of substance P analogs addressed using the "comprising"

language now removed from claims 26,27. Also claims 37-40 are added which are

directed to polypeptide that inhibits protein synthesis.

Claims 25-56 are pending.

Art Unit: 1631

## Claim Rejections - 35 USC § 112 (New matter)

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 41-56 rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claims contain subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventors, at the time the application was filed, had possession of the claimed invention. Claims 26,27 entered as Preliminary amendment on 03/30/2004, and now claims 41-56 (which inherited the "comprising" language of now amended claims 26,27) introduce new matter as they address substance P as "comprising" SEQ ID No. 1 or SEQ ID No. 2. Specification discloses substance P analog which is a peptide of SEQ ID No. 1 or 2 (as addressed now in claims 25-27, for example, but does not disclose a broader genus of substance P analogs comprising SEQ ID No. 1 or SEQ ID No. 2.

## **Double Patenting**

The double patenting rejection of record over claims of U.S. Patent No.6063758 is now moot in view of filing a Terminal Disclaimer.

Application/Control Number: 10/813,856 Page 4

Art Unit: 1631

Conclusion

Claims 25-41 are allowed.

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Michael Borin whose telephone number is (571) 272-

0713. The examiner can normally be reached on 9am-5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Marjorie Moran can be reached on (571) 272-0720. The fax phone number

for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the

Patent Application Information Retrieval (PAIR) system. Status information for

published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should

you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a

USPTO Customer Service Representative or access to the automated information

system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Michael Borin, Ph.D./

Primary Examiner, Art Unit 1631

Application/Control Number: 10/813,856

Page 5

Art Unit: 1631